Welcome to our dedicated page for Septerna SEC filings (Ticker: SEPN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to Septerna, Inc. (Nasdaq: SEPN) SEC filings, offering detailed regulatory disclosures about the company’s operations as a clinical-stage biotechnology company focused on G protein-coupled receptor (GPCR) drug discovery. As an issuer with common stock registered under Section 12(b) of the Exchange Act and listed on The Nasdaq Stock Market LLC or The Nasdaq Global Market, Septerna files current and periodic reports that describe its business, governance and financial condition.
Septerna’s Form 8-K filings frequently cover material events such as quarterly financial results and business highlights, including revenue, research and development expenses, general and administrative expenses, net income or loss, cash and marketable securities, working capital, total assets, total liabilities and stockholders’ equity. Other 8-Ks disclose collaboration agreements, such as the global collaboration and license agreement with Novo Nordisk A/S, leadership and board appointments, executive role changes, investor presentations and annual meeting voting results.
Through its SEC filings, Septerna also reports on matters like director elections, committee assignments, non-employee director compensation, and submission of matters to a vote of stockholders. These documents provide insight into the company’s corporate governance framework, including the composition of its board and committees and the outcomes of shareholder votes.
On Stock Titan, Septerna’s filings are updated in near real time as they are made available on EDGAR. AI-powered summaries help explain the key points of lengthy filings, so readers can quickly understand the implications of new 8-Ks and other reports without reviewing every page. Users can review historical filings to track trends in Septerna’s financials, follow the evolution of its collaborations and governance, and monitor ongoing disclosure about its GPCR-focused pipeline and clinical-stage programs.
Septerna, Inc. (SEPN) reported an equity award to Jeffrey Finer, who serves as Chief Executive Officer and a director. The filing shows a grant of a stock option to purchase 210,000 shares of common stock with an exercise price of $11.70 per share and an expiration date of 08/06/2035. The option vests in equal monthly installments equal to 1/48th of the shares, beginning with the monthly anniversary of August 1, 2025, subject to continuous service.
The reported position after the transaction is direct beneficial ownership of the 210,000 options. This disclosure documents a standard long‑term incentive award for the CEO with a multi‑year vesting schedule and a defined exercise price and expiration.
Septerna, Inc. insider Daniel D. Long, the company's SVP of Drug Discovery, received a grant of stock options allowing him to purchase 30,000 shares of Septerna common stock at an exercise price of $11.70 per share.
The option award was recorded with a transaction date of 08/07/2025, carries an expiration date of 08/06/2035, and vests in monthly installments equal to 1/48th of the total award beginning August 1, 2025, subject to continued service. The filing shows the reporting person holds 30,000 options following the transaction and lists the ownership form as direct.
Septerna, Inc. reporting person Uwe Klein, SVP, Biological Sciences, reported acquisition on Form 4 of 30,000 stock options on 08/07/2025. The options carry an exercise price of $11.70 and relate to 30,000 shares of common stock; they are shown as directly owned. The options are listed as exercisable beginning 08/06/2025 and subject to a vesting schedule where 1/48th of the shares vest in substantially equal monthly installments starting August 1, 2025, contingent on the reporting person's continuous service. The form was signed by attorney-in-fact Ran Xiao on 08/11/2025.
Septerna, Inc. reported a net loss of $46.3 million for the six months ended June 30, 2025, compared with a $30.6 million loss in the prior-year period. Revenue remained minimal at $0.3 million for the six months, generated from Vertex research services. Research and development expenses rose to $41.5 million and general and administrative expenses to $13.8 million, driving total operating expenses of $55.2 million. Cash used in operating activities was $43.6 million for the six months. The company had an accumulated deficit of $164.7 million as of June 30, 2025.
The company reported $189.3 million in cash and cash equivalents and $190.0 million of additional marketable securities (current and non-current) for total cash, cash equivalents and marketable securities of approximately $379.2 million, which management states is expected to fund operations for at least 12 months. Material agreements disclosed include a Collaboration and License Agreement with Novo Nordisk for multiple R&D programs with a $195.0 million upfront payment received in July 2025 and potential milestone and royalty payments, and a Vertex milestone payment realized in August 2025 of $12.5 million.
Septerna, Inc. announced that it released its financial results and business highlights for the quarter ended June 30, 2025 and furnished the related press release as Exhibit 99.1 to this Current Report. The filing states the press release is being furnished (and not "filed") for purposes of the Exchange Act, and the 8-K itself does not include detailed financial statements or metrics. Readers should consult Exhibit 99.1 for the substantive results and disclosures.
Insider Trading Alert: Shalini Sharp, Director at Septerna, was granted 16,623 stock options on June 17, 2025. The options have an exercise price of $10.24 per share and will expire on June 16, 2035.
Key details of the stock option grant:
- Vesting occurs in full upon the earlier of June 17, 2026, or the next annual stockholder meeting
- Vesting is contingent on continued service with the company
- The options represent the right to purchase 16,623 shares of common stock
- Transaction was filed under Form 4 as required by Section 16(a) of the Securities Exchange Act
This grant appears to be part of the company's director compensation program. The filing was completed through an attorney-in-fact, Jeffrey Finer, on June 20, 2025.
Director Jeffrey K. Tong of Septerna received a stock option grant on June 17, 2025, representing a significant insider transaction. The details include:
- Granted 16,623 stock options to purchase common stock
- Exercise price set at $10.24 per share
- Options expire on June 16, 2035
- Vesting schedule: 100% vests upon earlier of June 17, 2026 or next annual stockholder meeting
- Vesting conditional on continued service with company
This Form 4 filing represents a standard director compensation arrangement through equity incentives, aligning the director's interests with shareholders. The one-year cliff vesting structure suggests a retention mechanism while promoting long-term value creation.